-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Sabizabulin
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1332881-26-1.gif)
| Category | Human papillomavirus (HPV) |
| CAS | 1332881-26-1 |
| Description | Sabizabulin is a tubulin polymerization inhibitor with anti-tumor activity. |
Product Information
| Synonyms | ABI-231; ABI 231; ABI231; VERU 111 |
| IUPAC Name | [2-(1H-indol-3-yl)-1H-imidazol-5-yl]-(3,4,5-trimethoxyphenyl)methanone |
| Molecular Weight | 377.4 |
| Molecular Formula | C21H19N3O4 |
| Canonical SMILES | COC1=CC(=CC(=C1OC)OC)C(=O)C2=CN=C(N2)C3=CNC4=CC=CC=C43 |
| InChI | InChI=1S/C21H19N3O4/c1-26-17-8-12(9-18(27-2)20(17)28-3)19(25)16-11-23-21(24-16)14-10-22-15-7-5-4-6-13(14)15/h4-11,22H,1-3H3,(H,23,24) |
| InChIKey | WQGVHOVEXMOLOK-UHFFFAOYSA-N |
| Boiling Point | 688.1±55.0 °C at 760 mmHg |
| Purity | >98% |
| Density | 1.3±0.1 g/cm3 |
| Solubility | Soluble in DMSO |
| Appearance | Solid Powder |
| Storage | Store at -20°C |
| Complexity | 534 |
| Exact Mass | 377.13755610 |
| In Vitro | VERU-111 (2.5-80 nM; 24-48 hours) inhibits Panc-1, AsPC-1 and HPAF-II cells growth in a dose and time-dependent manner (24 hours: IC50s of 25, 35 and 35 nM, respectively; 48 hours: IC50s of 11.8, 15.5, and 25 nM, respectively). VERU-111 (5-20 nM; 24 hours) arrests Panc-1 and AsPC-1 cells in G2/M phase in a dose-dependent manner. VERU-111 (5-20 nM; 24 hours) shows dose-dependent inhibition of pro-Caspase 3 and 9 and activation of Caspase-3 and 9, induces the expression of Bax and Bad, and inhibits the expression of Bcl-2 and Bcl-xl proteins in both AsPC-1 and Panc-1 cells. |
| In Vivo | VERU-111 (50 μg/mouse; intra-tumorally; 3 times per week for 3 weeks) effectively inhibits tumor growth as compared to vehicle-treated group. None of the mouse showed any apparent toxicity as constant increase of body weight in VERU-111 treated mice. |
| Target | Microtubule/Tubulin; Apoptosis; HPV |
| XLogP3-AA | 3.4 |
